Impact of hormone receptor status on patterns of recurrence and clinical outcomes among patients with human epidermal growth factor-2-positive breast cancer in the National Comprehensive Cancer Network: a prospective cohort study. - Wikidata - awgldk - TriplyDB

Impact of hormone receptor status on patterns of recurrence and clinical outcomes among patients with human epidermal growth factor-2-positive breast cancer in the National Comprehensive Cancer Network: a prospective cohort study.

Impact of hormone receptor status on patterns of recurrence and clinical outcomes among patients with human epidermal growth factor-2-positive breast cancer in the National Comprehensive Cancer Network: a prospective cohort study.

http://www.wikidata.org/entity/Q33739253

about

Molecular and Genetic Predictors of Breast-to-Brain Metastasis: Review and Case Presentation Molecular subtypes and imaging phenotypes of breast cancer.Outcomes by tumor subtype and treatment pattern in women with small, node-negative breast cancer: a multi-institutional study.Differential impact of hormone receptor status on survival and recurrence for HER2 receptor-positive breast cancers treated with Trastuzumab Clinicopathological features among patients with advanced human epidermal growth factor-2-positive breast cancer with prolonged clinical benefit to first-line trastuzumab-based therapy: a retrospective cohort study.Molecular features and survival outcomes of the intrinsic subtypes within HER2-positive breast cancer Quality Assurance for Patients with Breast Cancer - the Impact of Clinical Cancer Registries.Predicting early brain metastases based on clinicopathological factors and gene expression analysis in advanced HER2-positive breast cancer patients.Response evaluation after primary systemic therapy of Her2 positive breast cancer – an observational cross-sectional study Patterns of Care and Clinical Outcomes of First-Line Trastuzumab-Based Therapy in HER2-Positive Metastatic Breast Cancer Patients Relapsing After (Neo)Adjuvant Trastuzumab: An Italian Multicenter Retrospective Cohort Study.Inhibition of the autocrine IL-6-JAK2-STAT3-calprotectin axis as targeted therapy for HR-/HER2+ breast cancers.Effect of HER2 status on distant recurrence in early stage breast cancer Immunohistochemical prediction of lapatinib efficacy in advanced HER2-positive breast cancer patients.Breast cancer brain metastases: new directions in systemic therapy ACTIVITY OF TRASTUZUMAB-EMTANSINE (TDM1) IN HER2-POSITIVE BREAST CANCER BRAIN METASTASES: A CASE SERIES.How relevant is hormone receptor status in the context of outcome to HER2-positive breast cancer?Molecular subtypes, histopathological grade and survival in a historic cohort of breast cancer patients.Prognostic Significance of Preoperative Circulating Monocyte Count in Patients With Breast Cancer: Based on a Large Cohort Study.Use and outcomes of targeted therapies in early and metastatic HER2-positive breast cancer in Australia: protocol detailing observations in a whole of population cohort.Bone metastasis risk factors in breast cancer.Guideline concordant therapy prolongs survival in HER2-positive breast cancer patients: results from a large population-based cohort of a cancer registry MR and mammographic imaging features of HER2-positive breast cancers according to hormone receptor status: a retrospective comparative study.Systemic Therapy for HER2-Positive Central Nervous System Disease: Where We Are and Where Do We Go From Here?Brain Metastases in Newly Diagnosed Breast Cancer: A Population-Based Study.Observational study on adjuvant trastuzumab in HER2-positive early breast cancer patients.Cyclin E amplification, over-expression, and relapse-free survival in HER-2-positive primary breast cancer.Clinical outcome of brain metastases differs significantly among breast cancer subtypes Disease progression pattern in metastatic breast cancer patients treated with anti-HER2 therapies.Prognostic Significance of Tumor-Infiltrating Lymphocytes and the Tertiary Lymphoid Structures in HER2-Positive Breast Cancer Treated With Adjuvant Trastuzumab.Potential clinical relevance of uPA and PAI-1 levels in node-negative, postmenopausal breast cancer patients bearing histological grade II tumors with ER/PR expression, during an early follow-up.Gene expression modules in primary breast cancers as risk factors for organotropic patterns of first metastatic spread: a case control study.Integrated evaluation of PAM50 subtypes and immune modulation of pCR in HER2-positive breast cancer patients treated with chemotherapy and HER2-targeted agents in the CherLOB trial.Fostering coordinated survivorship care in breast cancer: who is lost to follow-up?Trastuzumab distribution in an in-vivo and in-vitro model of brain metastases of breast cancer.Interplay between Natural Killer Cells and Anti-HER2 Antibodies: Perspectives for Breast Cancer Immunotherapy.Bone metastasis pattern in initial metastatic breast cancer: a population-based study.HER2-positive breast cancer: ¹⁸F-FDG PET for early prediction of response to trastuzumab plus taxane-based neoadjuvant chemotherapy.Correlations between molecular subtypes and pathologic response patterns of breast cancers after neoadjuvant chemotherapy.

P2860

Q26800626-E606B18C-4EA0-4235-8781-DAEB3354D652 Q28069885-C9065AC6-E337-46D5-9A8E-A6514BFC2F1B Q33824842-F729DC18-CFA6-41EE-88AF-A0EB7BA2CB07 Q33843810-50660471-A114-4D29-8FFC-A5513C3A2680 Q33855396-8EB4C034-B2AD-47D6-88F5-EA76CC501E98 Q34120668-788F503C-4D99-4638-A8C3-D58D2851BCC5 Q34243936-9AE9B2B3-47D9-469B-9BB4-4220011965E4 Q35159916-FAC4FFFA-6375-46EE-BE44-D9D646E7448A Q35539538-7B0D3844-1333-4638-A95D-B939BF7B64ED Q35915735-19331E9E-BC83-461A-8ADB-27051742854C Q35952745-BA5C541C-2521-4897-879E-30B08AD3E09E Q36530791-0F42363A-A9D6-486F-A9F4-A9F608203F8D Q36729467-9621D17B-34EB-4B49-A68E-7F4589636B5C Q36822500-D9BC8A2B-1417-48A3-815D-5709C28A5F0D Q36825346-C3F52875-C4E0-4DCF-A37A-D894610CA418 Q36903095-809571B5-B66F-4892-A437-B25E1024C28C Q37094017-DBEE5083-312B-4D45-9CEA-064ACA4098D9 Q37226075-7CAC3536-2113-4444-A4DD-A6B210AA93E2 Q37612139-27512C76-0EBE-4521-84AB-DA890174A229 Q37629662-61CA6160-DD64-43B2-A3EF-62F0E33511F5 Q37687943-5E5AA76E-797D-4402-91B9-50C2B8CE5E63 Q38409734-EA4CE3F9-ACAC-42B0-9D6B-F068B85A3A02 Q38575259-ABD184B8-F245-459E-8ADB-D1EB0117DC72 Q38903136-923B7E50-D248-478E-992B-1D033089E971 Q39036113-29253936-877A-47A9-93BA-0428BD9C2D89 Q40951473-4FD4F03F-F106-4F07-9E52-DBA3C49B68B5 Q40977689-8C60872D-18E7-4612-A975-A6EAA25C57AE Q41555316-FD0AD109-FE6E-47CF-86D9-884BF954B0B6 Q41576606-571F111E-04B7-468E-92C6-A23F21D326C9 Q41725997-96B87CF7-1B82-4020-A0EA-FFB60A75B9EB Q42377416-DE670689-8A17-4971-A762-251BEF886831 Q42497114-72D54781-6E2B-4C23-B7F4-D99FFBE94998 Q44870064-01FF783D-4BE0-4448-BA7F-9FEBCDB09BF5 Q45072965-C0E9DB98-0C39-4DC7-8B32-DE1A59AA15AE Q47156322-40C4B885-8B4D-4BC3-8C99-210DB88C6563 Q52691464-6BC86D66-6020-41C6-9465-69E93E12406C Q53074363-553BC247-FA10-4FA5-B918-275A8864E2B6 Q54324778-2AADE017-C441-45BD-A5FC-F2B8E2C9AEC4

P2860

Impact of hormone receptor status on patterns of recurrence and clinical outcomes among patients with human epidermal growth factor-2-positive breast cancer in the National Comprehensive Cancer Network: a prospective cohort study.

http://www.wikidata.org/entity/Q33739253

description

2012 nî lūn-bûn

@nan

2012 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Impact of hormone receptor sta ...... k: a prospective cohort study.

@ast

Impact of hormone receptor sta ...... k: a prospective cohort study.

@en

type

label

Impact of hormone receptor sta ...... k: a prospective cohort study.

@ast

Impact of hormone receptor sta ...... k: a prospective cohort study.

@en

prefLabel

Impact of hormone receptor sta ...... k: a prospective cohort study.

@ast

Impact of hormone receptor sta ...... k: a prospective cohort study.

@en

P1433

Q33739253-A525ED73-49D5-4847-8C1F-30EF8C171092

P1476

Q33739253-305DD680-B78E-47D9-9898-1FED74CD099E

P2093

Q33739253-086B9F9E-0453-4F47-BA7B-4DC31D9E5FAE

Q33739253-31102247-C057-4F7F-8850-7DE9115F0858

Q33739253-46227560-CCB7-423D-AAE0-83B6829E2997

Q33739253-487B7E8F-830D-4FAB-9B9A-E2BDDA34251D

Q33739253-5934B157-FA55-414C-8096-1CE843AAD9D8

Q33739253-89069F94-7F75-4101-B894-A36D6F0BE7AF

Q33739253-8FF728F2-F5E7-4EA6-9F73-A56903080BC8

Q33739253-9C555117-FF74-4833-9A24-B9132BB36681

Q33739253-C63F1F62-A013-4BC5-AEDB-57FA2FD7B195

Q33739253-E0E71887-683D-4AAE-9129-28315188BC2F

P2860

Q33739253-0183C181-263E-4657-BAFA-31A9149F52B4

Q33739253-0348A9E2-9751-4C1E-ACA4-EDEB34BA2AD9

Q33739253-07CCB0EE-AAFB-42B8-9B2C-D302A25B9ACE

Q33739253-099A162A-42CA-4230-B6C2-FAB0789E8798

Q33739253-140A1AC3-43EA-458C-B481-C0EE8B900BFA

Q33739253-1723AA96-1087-4B03-8BA9-81D90E449A59

Q33739253-1E00100F-47DF-4C32-874F-B5958A16FF09

Q33739253-24DF820C-CDB9-4A94-8A55-431099791E60

Q33739253-30846E4E-8325-402A-BEAF-0AC49A9A984A

Q33739253-311525B6-640B-498D-AAF4-BCB0E47188CF

P2888

Q33739253-C91A7FCD-F813-4F9D-A187-E1A71461CE40

P304

Q33739253-5B581DCE-69F0-418A-A2F7-69D7C278FA37

P31

Q33739253-A60F4972-76C3-4990-A9D6-C9A5F5B9AE9B

P356

Q33739253-B4B46E74-0E23-44D2-B9CB-A58134C0E6F5

P433

Q33739253-CCAF292A-1CD4-4FBB-A475-63AEE8E77274

P478

Q33739253-37EAC9CA-3DE6-4D4D-937F-7AB5EC1AB4CA

P577

Q33739253-8D007CD1-CCAC-4C0D-B48E-50076FACE76B

P5875

Q33739253-8BAAC6EB-6514-40A4-8065-133257D48D57

P6179

Q33739253-6BEFB4E8-A30C-4296-8CBA-F61F7B04AC8A

P698

Q33739253-A02EF93D-922F-4D6B-BEBE-C01C319A5184

P932

Q33739253-77B56C8A-4C54-406C-8856-BB2793EE580A

P356

P1433

Breast Cancer Research

P1476

Impact of hormone receptor sta ...... k: a prospective cohort study.

@en

P2093

Beverly Moy

http://www.w3.org/2001/XMLSchema#string

Hope S Rugo

http://www.w3.org/2001/XMLSchema#string

Ines Vaz-Luis

http://www.w3.org/2001/XMLSchema#string

Jane C Weeks

http://www.w3.org/2001/XMLSchema#string

John Wilson

http://www.w3.org/2001/XMLSchema#string

Joyce C Niland

http://www.w3.org/2001/XMLSchema#string

Melissa E Hughes

http://www.w3.org/2001/XMLSchema#string

Nancy U Lin

http://www.w3.org/2001/XMLSchema#string

P Kelly Marcom

http://www.w3.org/2001/XMLSchema#string

Rebecca A Ottesen

http://www.w3.org/2001/XMLSchema#string

P2860

Genes that mediate breast cancer metastasis to the brain

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial.

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

Gene expression profiling predicts clinical outcome of breast cancer

Molecular portraits of human breast tumours

Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial

A new method of classifying prognostic comorbidity in longitudinal studies: development and validation

Genes that mediate breast cancer metastasis to lung

A multigenic program mediating breast cancer metastasis to bone

P2888

P304

R129

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/BCR3324

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

14

http://www.w3.org/2001/XMLSchema#string

P577

2012-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

231740541

http://www.w3.org/2001/XMLSchema#string

P6179

1021547000

http://www.w3.org/2001/XMLSchema#string

P698

23025714

http://www.w3.org/2001/XMLSchema#string

P932

4053106

http://www.w3.org/2001/XMLSchema#string